Inactive Instrument

BioNTech SE Stock Xetra

Equities

US09075V1026

Biotechnology & Medical Research

Sales 2024 * 2.8B 3.03B Sales 2025 * 2.77B 3B Capitalization 21.55B 23.38B
Net income 2024 * -435M -472M Net income 2025 * -508M -551M EV / Sales 2024 * 2.42 x
Net cash position 2024 * 14.78B 16.02B Net cash position 2025 * 13.76B 14.92B EV / Sales 2025 * 2.82 x
P/E ratio 2024 *
-49.5 x
P/E ratio 2025 *
-44.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 58 08-06-01
Founder 57 08-06-01
Director of Finance/CFO 60 21-06-30
Members of the board TitleAgeSince
Director/Board Member 69 21-12-31
Director/Board Member 67 08-06-01
Chairman 53 08-06-01
More insiders
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
More about the company